Dr Reddy’s launches 2-DG to treat Covid

DR Reddy’s Laboratories announced the commercial launch of 2-deoxy-D-glucose (2-DG) drug for Covid-19 on Monday.

Published: 29th June 2021 09:02 AM  |   Last Updated: 29th June 2021 09:02 AM   |  A+A-

By Express News Service

HYDERABAD: DR Reddy’s Laboratories announced the commercial launch of 2-deoxy-D-glucose (2-DG) drug for Covid-19 on Monday. It was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy’s.

2-DG is an oral drug, which can be administered only on prescription and under the supervision of a qualified physician to hospitalised patients with moderate to severe Covid-19 symptoms as an adjunct therapy to the existing standard of care. Emergency use approval for the drug was granted on May 1, 2021. In a press release, Dr Reddy’s said that it will supply the medicine to major government as well as private hospitals across India.

The company said that in the initial weeks it will make the drug available in hospitals across all metro cities and Tier 1 cities, and subsequently, expand the coverage to the rest of India. The medicine has a purity of 99.5 per cent. The MRP of each 2-DG sachet has been fixed at `990 and the price will be subsidised for government institutions. Dr Reddy’s Laboratories Chairman, Satish Reddy, said, “We are extremely pleased to have partnered with DRDO in our collective fight against the Covid-19 pandemic.”


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp